Loading…

Loading grant details…

Active HORIZON European Commission

PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification

€4.6M EUR

Funder European Commission
Recipient Organization Athens University of Economics and Business - Research Center
Country Greece
Start Date Oct 01, 2022
End Date Sep 30, 2027
Duration 1,825 days
Number of Grantees 12
Roles Participant; Coordinator; Associated Partner
Data Source European Commission
Grant ID 101057746
Grant Description

Radiotherapy is a widely used cancer treatment, however some patients suffer side effects. In breast cancer, side effects can include breast atrophy, arm lymphedema, and heart damage.

Some factors that increase risk for side effects are known, but current approaches do not use all available complex imaging and genomics data. The time is now ripe to leverage the huge potential of AI towards prediction of side effects.

This project will use rich datasets from three patient cohorts to design and implement an AI tool that predicts the risk of side effects, including arm lymphedema in breast cancer patients and provides an easily understood explanation to support shared decision-making between the patient and physician.

The PRE-ACT consortium combines the expertise in computing (MDW, AUEB-RC), AI (HES-SO, CENTAI), radiation oncology (MAASTRO, UNICANCER), medical physics (THERA), genetics (ULEIC), psychology (CNR) and health economics (UM) that is necessary to tackle this problem.The project will integrate data from the three cohorts and build AI predictive models with built-in explainability for each of the key side effects of breast cancer radiotherapy.

These AI models will be incorporated into an existing commercial radiotherapy software platform to create a world-leading product.

The extended platform will be validated in a clinical trial to support treatment decisions regarding the irradiation of lymph nodes.

The trial will adopt an innovative design in which the patients and medical team in the test arm will receive the risk prediction, but those in the control arm will not.

A communication package built with a co-design methodology will ensure that AI outcomes are tailored to stakeholders effectively.

The trial will evaluate whether using the AI platform changed the arm lymphedema rate and impacted treatment decisions and quality-of-life. Generalizability of the AI models for other types of cancer will be sought through transfer learning techniques.

All Grantees

Centai Institute Spa; Unicancer; Universiteit Maastricht; Stichting Maastricht Radiation Oncology Maastro Clinic; Consiglio Nazionale Delle Ricerche; Medical Data Works Bv; Istituto Per L'Interscambio Scientifico; Athens University of Economics and Business - Research Center; Haute Ecole Specialisee de Suisse Occidentale; University of Leicester; Therapanacea; Mirada Medical Ltd

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant